|

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

RECRUITINGSponsored by National Cancer Institute (NCI)
Actively Recruiting
SponsorNational Cancer Institute (NCI)
Started2014-03-25
Est. completion2100-01-01
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT02610439

Summary

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* European American patients with DNA available and designated case or control
* African American patients with DNA available and designated case or control status
* Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel

Conditions4

Breast CancerBreast CarcinomaCancerNeuropathy

Locations1 site

Eastern Cooperative Oncology Group
Boston, Massachusetts, 02215
Bryan P. Schneider317-274-6473bpschnei@iupui.edu

Browse More Trials

Cancer trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.